Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 5/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 11/20 | 0.86 |
| ▸ | PGR | P06401 | 4/20 | 0.86 |
| ▸ | AR | P10275 | 3/20 | 0.86 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.86 |
| ▸ | LMNA | P02545 | 2/20 | 0.86 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.86 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SHBG | P04278 | 1/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone Phosphoric Acid SCHEMBL42271 | 0.95 | HIF1A (0.77) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Phosphoric Acid SCHEMBL1761098 | 0.95 | HIF1A (0.77) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Phosphoric Acid SCHEMBL19459282 | 0.95 | HIF1A (0.77) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Phosphoric Acid SCHEMBL21647387 | 0.94 | HIF1A (0.75) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL4940901 | 0.93 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL7419 | 0.93 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL13026148 | 0.93 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL2679809 | 0.93 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL2452043 | 0.93 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA | |
| Hydrocortisone Acetate SCHEMBL25599370 | 0.93 | HIF1A (1.00) | HIF1APGRARSERPINA6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11965025-B2 | Method of treating solid cancers with bispecific interleukin-anti-TCRß molecules | MARENGO THERAPEUTICS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024081381-A1 | MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024081329-A1 | MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240076377-A1 | ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF | MARENGO THERAPEUTICS, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4328241-A2 | MULTISPECIFIC MOLECULES COMPRISING A NON-IMMUNOGLOBULIN HETERODIMERIZATION DOMAIN AND USES THEREOF | Marengo Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024035859-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2024035864-A1 | COMBINATION OF QUERCETIN AND PATHENOLIDE AS ANTI-INFLAMMATORY AGENTS FOR USE IN THE TREATMENT OF DERMATITIS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4320147-A2 | MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | Marengo Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20240002543-A1 | MULTIFUNCTIONAL MOLECULES THAT BIND TO CALRETICULIN AND USES THEREOF | MARENGO THERAPEUTICS INC (US) | 2024-01-04 | — | — | US | disclosed |
| EP-3615566-B1 | MULTISPECIFIC MOLECULES COMPRISING A NON-IMMUNOGLOBULIN HETERODIMERIZATION DOMAIN AND USES THEREOF | MARENGO THERAPEUTICS INC (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2018057955-A1 | MULTISPECIFIC ANTIBODY MOLECULES COMPRISING LAMBDA AND KAPPA LIGHT CHAINS | ELSTAR THERAPEUTICS, INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-20180064662-A1 | NOVEL COMPOSITIONS AND USES OF METFORMIN AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170368169-A1 | MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF | MARENGO THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2017165464-A1 | MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF | ELSTAR THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017106630-A1 | POLYACETAL POLYMERS, CONJUGATES, PARTICLES AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-2866791-A1 | NOVEL COMPOSITIONS AND USES OF ANTI-HYPERTENSION AGENTS FOR CANCER THERAPY | The General Hospital Corporation (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2013169739-A1 | NOVEL COMPOSITIONS AND USES OF ANTI-HYPERTENSION AGENTS FOR CANCER THERAPY | THE GENERAL HOSPITAL CORPORATION (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130287688-A1 | NOVEL COMPOSITIONS AND USES OF ANTI-HYPERTENSION AGENTS FOR CANCER THERAPY | XTUIT PHARMACEUTICALS, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| EP-2640359-A2 | NOVEL COMPOSITIONS AND USES OF ANTI-HYPERTENSION AGENTS FOR CANCER THERAPY | The General Hospital Corporation (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068531-A2 | NOVEL COMPOSITIONS AND USES OF ANTI-HYPERTENSION AGENTS FOR CANCER THERAPY | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064662-A1 | NOVEL COMPOSITIONS AND USES OF METFORMIN AGENTS | COL2A1, COL1A1, MMP1 | NR3C1 2028/4885HIF1A 6/4885PGR 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.